Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colorectal resection cases in New Hampshire: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 413 | 21% |
| 2020 | 1 | 362 | 25% |
| 2021 | 0 | 341 | 29% |
| 2022 | 1 | 310 | 33% |
| 2023 | 1 | 322 | 37% |
| 2024 | 1 | 334 | 39% |
| 2025 from claims | – | 331 268–389 | 40% |
| 2026 forecast | – | 369 289–463 | 35% |
| 2027 forecast | – | 381 283–504 | 34% |
| 2028 forecast | – | 394 279–543 | 34% |
| 2029 forecast | – | 407 276–583 | 33% |
| 2030 forecast | – | 420 275–623 | 33% |
Laparoscopic and open colectomy and proctectomy; stapler, energy, and robotics call point. Professional codes (what the surgeon bills): CPT 44204, 44205, 44207, 44140, 44145, 44160, 45395, 45397; the hospital bills MS-DRG 329, 330, 331.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Hampshire; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 15 | 2,669−5%/yr | −5%/yr | 1.5 | 0% | 2,770 in 2030+0.6%/yr |
| Pennsylvania | 12 | 2,424−5.6%/yr | −5.6%/yr | 1.8 | 0% | 2,120 in 2030−2.2%/yr |
| New Jersey | 8 | 1,527−3%/yr | −3%/yr | 1.5 | 0% | 1,740 in 2030+2.2%/yr |
| Massachusetts | 10 | 1,485−3.1%/yr | −3.1%/yr | 1.6 | 0% | 1,660 in 2030+1.9%/yr |
| Connecticut | 2 | 469−8.4%/yr | −8.4%/yr | 1.5 | 0% | 480 in 2030+0.5%/yr |
| Maine | 1 | 264−7.9%/yr | −7.9%/yr | 1.7 | 0% | 170 in 2030−7.1%/yr |
| Vermont | 0 | 141+1.5%/yr | +1.5%/yr | 1.3 | 0% | 150 in 2030+1%/yr |
| Rhode Island | 0 | 116−12%/yr | −12%/yr | 1.3 | 0% | 230 in 2030+12%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 13 | 1,120−0.6%/yr | −0.6%/yr | 5.20.9× | 2% | 1,720 in 2030+7.5%/yr |
| Cholecystectomy & appendectomy | 6 | 766−3%/yr | −3%/yr | 3.41.0× | 2% | 990 in 2030+4.4%/yr |
| Antireflux & hiatal hernia surgery | 1 | 142+1.5%/yr | +1.5%/yr | 0.61.0× | 0% | 220 in 2030+7.4%/yr |
| Bariatric surgery | 0 | 103−3.3%/yr | −3.3%/yr | 0.42.7× | 0% | 90 in 2030−2.3%/yr |
Colorectal resection in every state, and its device makers · Every procedure market in New Hampshire · Every state · Compare with New York
Intuitive Surgical leads with 89% of company spending on these surgeons in 2025, +1 pts on 2024.
In 2025, 3 companies reported engagement with New Hampshire’s surgeons worth $42K in consulting, speaking, meals and travel tied to these products, about $42K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.